1 The plasma decay, tissue uptake and biotransformation of radiolabelled phosphatidylserine (PS) liposomes have been investigated in rats following bolus i.v. injection (2 mg kg-1). 2 PS plasma concentration showed a biexponential decay with half-lives of 0.85 and 40min. The following interpretation of the biphasic decay is proposed: (1) The rapid initial decline is due to the irreversible uptake of PS liposomes by the mononuclear phagocyte system, as demonstrated by the almost exclusive accumulation of PS in liver and spleen. (2) The slow decay phase reflects the elimination of that fraction of PS that has been incorporated into high density plasma lipoproteins (HDL). A kinetic model has been developed to describe these phenomena and a good agreement has been observed between experimental data and theoretical values. 3 Evidence has been obtained that a large fraction of PS is hydrolyzed at the injection site, probably by phospholipase A2 and other hydrolytic enzymes released by platelets. Hydrolysis at the injection site has also been observed following intraperitoneal and intramuscular injections. 4 As shown by the comparative analysis of the biotransformation products found in tissues after administration of either [3H]-glycerol-PS or ["4C]-serine-PS, parenterally administered PS follows two distinct metabolic pathways: (1) decarboxylation to phosphatidylethanolamine and (2) extensive hydrolytic degradation with release of the individual components of the molecule. These pathways probably reflect the two main mechanisms of PS uptake, incorporation into the plasma membrane and internalization by endocytosis, respectively.
Introduction
Our initial studies (Bruni et al., 1976; Bigon et al., 1979ab) have shown that parenteral administration of phosphatidylserine (PS) to rodents induces complex pharmacological effects. These are believed to reflect a pathophysiological role of PS and its lysoderivative in the immune and the inflammatory responses (Mietto et al., 1987) . Consistently, macrophages, lymphocytes and mast cells have been shown to be target cells for serine phospholipids in vivo and in vitro. The interaction of PS with macrophages appears to be mediated by the scavenger receptor (Nishikawa et al., 1990) . As a consequence, cells exposing PS at the external membrane surface are internalized and eliminated by macrophages (Tanaka & Schroit, 1983; Schroit et al., 1985) . PS uptake is not without consequences for macrophages as it has been demonstrated that ingestion of liposomes containing this phospholipid reduces the microbicidal activity against intracellular leishmanias (Gilbreath et al., 1986) . In lymphocytes, PS is incorporated by an energy-dependent process which might involve endocytosis, internalization by the translocator for the aminophospholipids or a deacylation-reacylation cycle (Mietto et al., 1989) . Decreased secretion of interleukin-2 follows PS incorporation (Ponzin et al., 1989) . Unlike macrophages and lymphocytes, mast cells undergo activation after the interaction with PS and lysoPS. The secretion of mast cell mediators is the result of phosphoinositidase C activation (Bellini et al., 1988; . The in vivo disposition of phospholipid liposomes supports the possibility of an action of PS on the immune system. Several studies have indeed shown that parenteral administration of these lipid structures is followed by their accumulation in organs (liver, spleen, lungs) which are rich in immunocompetent cells (reviewed by Poste, 1983) . However, the pharmacokinetic properties of liposomes have been thus far investigated in relation to their use as drug carriers. For this reason only the disposition of long-lived liposomes, such as those containing phosphatidylcholine (PC), sphingomyelin (SPH) or cholesterol as basic components, has been exten- ' Author for correspondence. sively studied (Gregoriadis & Neerunjun, 1974; Allen & Everest, 1983; Gabizon & Papahadjopoulos, 1988 and references therein) . In spite of their intrinsic pharmacological activity, liposomes made up exclusively of PS have not yet been characterized from a pharmacokinetic point of view. The purpose of this study is to provide essential kinetic data pertaining to the intravenous administration of PS liposomes in the rat.
Methods Phosphatidylserine
Conventional preparations of bovine brain PS (Bigon et al., 1979a) were further purified on DEAE-cellulose to remove a small amount of phosphatidylinositol (Rouser et al., 1969) . The phospholipid was stored at -20'C as a solution in chloroform-methanol (2:1, v/v) at a concentration of 10-20mg ml-1, quantified by periodic phosphorus determinations.
Phosphatidyl-['4C]-serine
(160 mCi mmol -) contained 4% of hydrosoluble radioactivity and 1% of lysoPS (Orlando et al., 1980 Hwang et al. (1980) showed that the contribution to tissue radioactivity from residual blood content was in fact negligible.
Phospholipids were extracted from plasma and tissues immediately after sampling, by 20 volumes of chloroformmethanol (2:1, v/v). The filtered lipid extract was washed with 0.2 volumes of 1O mm CaCI2 and resolved by two dimensional thin layer chromatography (Punzi et al., 1986) . The radioactivity of the samples was determined in a Packard Tricarb 2200 CA liquid scintillation system, using the computerized automatic external standard for quench correction.
Pharmacokinetic analysis
The plasma decay of PS liposomes after bolus i.v. injection was analyzed by means of the kinetic model depicted in Figure 1 . The basic assumption of the model is that exit of PS liposomes out of the plasma compartment is a unidirectional process. With the possible exception of very small unilamellar vesicles (less than 60nm in diameter) phospholipid liposomes are unable to cross either continuous or fenestrated capillaries (Poste, 1983; Hwang & Beaumier, 1988) . Their extravasation is limited to tissues containing sinusoidal capillaries and appears predominantly due to endocytosis by the local macrophages, although fusion with cell membranes, deacylationreacylation or interaction with the transporter for the amino phospholipids may also be operative for PS (Bruni & Palatini, 1982; Mietto et al., 1989) . After internalization by endocytosis, phospholipid vesicles are degraded by lysosomal enzymes, whereas the other pathways result in the incorporation of liposomal phospholipids into the phospholipid pool of the cellular membrane. A significant incorporation of liposomal phospholipids occurs also in plasma by high density lipoproteins (HDL) (see, e.g. Scherphof et al., 1978; Vidal et al., 1984; William & Tall, 1988 liposomes (Damen et al., 1981) , or the concentration of HDL phospholipid is in excess over that of liposomes (Bienvenue et al., 1985) phospholipid transfer from liposomes to HDL is an irreversible process, the rate of which depends solely on the liposomal phospholipid concentration. Phospholipids incorporated into HDL are then removed from plasma by reactions involving the uptake of the whole lipoprotein or the independent movement of the lipid moiety (Eisenberg, 1984) . A metabolic elimination route from the plasma compartment is also included in the model, since PS was found to be hydrolyzed in the plasma of rats to lysoPS and hydrosoluble compounds (mainly serine). The model shown in Figure 1 is described by the following differential equations:
where K = k, + k3 + k4, and F designates liposomes).
where B indicates PS bound to HDL. The solution for equation 1 is:
(3) where C0 is the zero-time concentration of PS. Substituting equation 3 into equation 2 and solving for [B] yields [B] kek2t -e-Kt K -k
The total concentration of PS in plasma,
, is given by
PS plasma concentration-time data were fitted to equation 5 by a weighted (1/C2), computer-assisted, non-linear least squares regression analysis.
Results
Kinetics ofphosphatidylserine Figure 2 illustrates the time course of the plasma concentrations of PS (a) and its degradation products (b) following bolus intravenous injection. The concentration of PS showed a biphasic decline with a very rapid initial decay (Figure 2a) . Assuming a plasma volume of 40 ml kg'- (Hwang et al., 1980) it could be calculated that 93% of the injected phospholipid was removed from plasma within 3min. explaining the unusually rapid initial disa from plasma. A similarly rapid initial decay centration has been previously observed (1980) . Although the injected vesicles also terol which has a stabilizing effect, 90% of P. removed from plasma within 4min. Since t sure of the jugular vein might favour platelet release of hydrolytic enzymes, the phosp injected into the tail vein. By this route sir stants for PS were obtained. The initial metabolites was somewhat reduced, but nc radioactivity associated with lysoPS at 30s 103 d.p.m. ml-', in comparison to 7.9 + 1.4 after injection into the jugular vein; means + rats, respectively). In situ degradation of PS i after intraperitoneal or intramuscular (poste (Tables 3 and 5 ) it can be estimated that serine accounts approximately for 10-13 radioactivity found in spleen and liver aft of ["4C]-serine-PS.
Discussion
In this study the disposition of intraveno cles has been investigated to see whether with the pharmacological actions obser parenteral administration. Previous inmv pholipid vesicles of various compositic main patterns of interaction with tissue, , 1978; William & Tall, 1988) . Qualitatively, these events are independent of liposome charge, structural class (mono-or multi-lamellar) and composition (Poste, 1983) . However, they are amplified when the vesicle size is large (Juliano & Stamp, 1975; Patel & Ryman, 1981) or certain functional groups, such as the phosphorylserine group, are present. Recent iusly injected PS vesireports have indeed shown that this functional group is sper a relationship exists cifically recognized by the mononuclear phagocyte system wed in rodents after (Tanaka & Schroit, 1983; Allen et al., 1988) and accelerates estigations on phos-the rate of liposome interaction with HDL (Bienvenue et (Schroit et al., 1985;  urml-e x 10-3 Mietto et al., 1989; Ponzin et al., 1989) . (Stein & Stein, 1966 Stamp, 1975; Patel & Ryman, 1981) . With PS-containing lipo-!r Spleen somes, however, the disappearance from plasma has been rat 2 rat I rat 2 shown to be independent of the vesicle size (Juliano & Stamp, 1975 (Juliano & Stamp, 1975; Kao & Loo, 1980 lOOmgkg-1) far higher than those employed in this study (2mgkg-'). In the case of PS, saturation at this dose would imply a very low capacity uptake by the macrophage scavenger receptor that is expected to mediate the endocytosis of vesicles containing this phospholipid (Nishikawa et al., 1990) .
The combined use of [3H]-glycerol-PS and ["4C]-serine-PS enabled us to outline the metabolic fate of injected PS. Extensive hydrolysis occurs at the injection site yielding, in addition to hydrosoluble metabolites, the pharmacologically active compound lysoPS. The production of lysoPS is most likely due to the phospholipase A2 released by the platelet aggregating at the site of the perforated vessel. Rat platelets are known to be rich in phospholipase A2 acting on PS (Horigome et al., 1987) . Formation of lysoPS at the injection site, although in small amounts, is also observed after intramuscular or intraperitoneal injection. These observations indicate that there might be a variable contribution of lysoPS to the pharmacological actions of PS, depending on the route of administration.
After incorporation into tissues, PS follows two metabolic pathways which reflect the two main mechanisms of uptake. One involves decarboxylation to PE of a minor fraction (8% in the liver) of the incorporated PS. Since this is the physiological pathway of PS metabolism, it most probably involves that fraction of PS that mixes with the phospholipid pool of the plasma membrane. The other, predominant, metabolic pathway proceeds to the complete hydrolysis of PS to the individual components of the molecule as testified by the detection in tissues of labelled glycerol and serine. This sequence is to be expected if the phospholipid vesicle is internalized by endocytosis and hydrolyzed after fusion of the endocytic vacuole with lysosomes (Dijkstra et al., 1985) . Consistently, PS uptake is predominant in organs (liver and spleen) where endocytosis by the local macrophage population is especially active.
